Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 2006 + web + 0.40  Related to the article below (Last Update: 8/4/2008)

ScottsMiracle-Gro Announces Record Third Quarter Sales Based on ...
PR Newswire (press release), NY - Jul 31, 2008
The call will be available live on the investor relations section of the ScottsMiracle-Gro Web site, http://investor.scotts.com An archive of the Webcast, ...SMG
Percutaneous Spine Biopsy: A Meta-Analysis
Journal of Bone and Joint Surgery (subscription) - Aug 1, 2008
Although studies involving the use of computed tomography demonstrated slightly higher rates for adequacy (92.6% compared with 90.1%, p = 0.40) and accuracy ...
CPN In-Fill & Delineation Drilling on the Rovina Porphyry, Romania ...
FOXBusiness - Jul 23, 2008
Copper is analyzed using the industry-standard method of aqua-regia digest on a 0.40 -gram sub sample with an AAS finish. Coarse blanks, pulp blanks, ...TSE:CPN - OTC:CMTX
InvestSource, Inc.: Hunt Gold Corporation Discusses Takeover
Trading Markets (press release), CA - Aug 1, 2008
The Rain Mine reportedly hosts an average grade of 0.40 oz/ton gold and Newmont estimated the resource potential at over 2.0 million ounces of gold over a ...PINK:HGLC - GG - NG
Are Dividends the Cure for Your Ailing Portfolio?
Morningstar.com, IL - Jul 29, 2008
It features a nice 3.42% yield and a 0.40% expense ratio. Vanguard also offers an exchange-traded fund, Vanguard Dividend Appreciation , that's even cheaper ...
Fraser Papers Announces Second Quarter Financial Results
MarketWatch - Jul 31, 2008
The conference call can also be accessed via web cast on the Fraser Papers web site at www.fraserpapers.com. Fraser Papers is an integrated specialty paper ...TSE:FPS

The Associated Press
Drinking games prove deadly to college students
The Associated Press - Jul 7, 2008
Some universities are trying to send the same message with Web sites and programs that feature slogans such as "Remember Last Night. ...
Canadian Oil Sands Trust raises quarterly distribution to $1.25 ...
FOXBusiness - Jul 29, 2008
Syncrude has participated in this program since inception and had its results externally verified in both 2006 and 2007. Syncrude received two awards for ...TSE:COS.UN
Banner Corporation Announces Second Quarter Results; Includes ...
MarketWatch - Jul 28, 2008
Visit Banner Bank on the Web at www.bannerbank.com. This press release contains statements that the Company believes are "forward-looking statements. ...BANR - KIDS
Conexant Reports Financial Results for the Third Quarter of Fiscal ...
Trading Markets (press release), CA - Jul 31, 2008
To listen via the Internet, visit the Investor Relations section of Conexant's Web site at www.conexant.com/ir. Playback of the conference call will be ...CNXTD
Source: Google News

A reference collection for web spam -
C Castillo, D Donato, L Becchetti, P Boldi, S … - ACM SIGIR Forum, 2006 - portal.acm.org
... 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 ... C., Donato, D., Leonardi, S., and
Baeza-Yates, R. (2006). ... In Proceedings of the Workshop on Web Mining and ...

[PDF] Web searcher interaction with the Dogpile. com metasearch engine -
BJ Jansen, A Spink, S Koshman - Journal of the American Society for Information Science and …, 2007 - ist.psu.edu
... 9 5,757 0.4% ... This is similar to what was found for users of other Web search en ... (2006)
found that the most frequently used Vivisimo terms used were download, new ...
-

Detecting spam web pages through content analysis -
A Ntoulas, M Najork, M Manasse, D Fetterly - … of the 15th international conference on World Wide Web, 2006 - portal.acm.org
... WWW 2006, May 23?26, 2006, Edinburgh, Scotland. ... score 1, since 100% of the words
on the web page were ... 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 ...

[PDF] Genre classification of web pages
B Stein, S Meyer zu Eissen - Proceedings of the 27th German Conference on Artificial …, 2004 - ling.uni-potsdam.de
Genre Classification of Web Pages Benno Stein Bauhaus University Weimar Web Technology
and IS Group ... Stein Background: How to Satisfy a Web Information Need ...

Which factors explain the web impact of scientists? personal homepages -
F Barjak, X Li, M Thelwall - Journal of the American Society for Information Science and …, 2007 - doi.wiley.com
... in the life sciences (Thelwall, Barjak, & Kretschmer, 2006). ... more organized (hence,
more interlinked) Web sites. ... All scientists 2.3 (0.3) 2.5 (0.4) 4.8 (0.6) ...

Lipid headgroup superlattice modulates the activity of surface-acting cholesterol oxidase in ternary … -
KH Cheng, B Cannon, J Metze, A Lewis, J Huang, MW … - Biochemistry, 2006 - pubs.acs.org
... 10.1021/bi060937y S0006-2960(06)00937-8 Web Release Date ... Revised Manuscript Received
June 21, 2006. ... COD activity changed abruptly at X CHOL 0.40, whereas major ...

A comparison of implicit and explicit links for web page classification -
D Shen, JT Sun, Q Yang, Z Chen - … of the 15th international conference on World Wide Web, 2006 - portal.acm.org
... World Wide Web Conference Com- mittee (IW3C2). Distribution of these papers is limited
to classroom use, and personal use by others. WWW 2006, May 23?26, 2006 ...

Finding near-duplicate web pages: a large-scale evaluation of algorithms -
M Henzinger - Proceedings of the 29th annual international ACM SIGIR …, 2006 - portal.acm.org
... Copyright 2006 ACM 1-59593-369-7/06/0008 ... 569 pages and is mostly due to two data
bases on the web. ... 0.47 0.37 0.16 (0.10) 382 > C-sim = 379 407 0.40 0.37 0.23 ...

A Task-Based Approach to User Interface Design for a Web-Based Hydrologic Information Systems -
LK Soh, J Zhang, A Samal - Transactions in GIS, 2006 - Blackwell Synergy
... Journal compilation ? 2006 Blackwell Publishing Ltd Research Article A Task-Based
Approach to User Interface Design for a Web-Based Hydrologic ...

Web Release Date: October 20, 2006 -
MD Hurley, JC Ball, TJ Wallington, MPS Andersen, … - J. Phys. Chem. A, 2006 - pubs.acs.org
... 10.1021/jp064029m S1089-5639(06)04029-1 Web Release Date: October 20 ... In Final Form:
August 17, 2006. ... 10 -17 , (1.90 ? 0.17) ? 10 -19 , (5.04 ? 0.40) ? 10 -20 ...

Source: Google Scholar
 
 

Gene Therapy For Hereditary Lung Disease Advances

Article Date: 27 Nov 2006 - 11:00am (PST)
An experimental gene therapy to combat alpha-1 antitrypsin deficiency, a common hereditary disorder that causes lung and liver disease, has caused no harmful effects in patients and shows signs of being effective, University of Florida researchers say.

In a clinical trial, researchers evaluated the safety of using a so-called gene vector - in this case an adeno-associated virus - to deliver a corrective gene to 12 patients who are unable to produce a protein essential for health called alpha-1 antitrypsin.

"The primary end point in the trial was to see whether it was safe to give patients this gene transfer vector and then to try to begin to see if we could get the dose into a range where we would begin to replace the missing protein in the blood," said Terence Flotte, M.D., a pediatrician, geneticist and microbiologist with UF's College of Medicine and a member of the Powell Gene Therapy Center and the UF Genetics Institute. "We found that we can use this agent safely and we also saw evidence in the patients' blood that the higher doses successfully introduced the vector DNA. In one patient we saw evidence for a very brief period that some of the alpha-1 protein was being produced, but not at a high enough level to be beneficial."

The findings appear online today (Nov. 21) in the journal Human Gene Therapy.

Physicians injected doses of the virus containing copies of the gene for alpha-1 antitrypsin into the patients' upper arms. Essentially, the virus is intended to "infect" patients' cells with replacement genes that will do the necessary work to produce alpha-1 protein. UF scientists have successfully developed the technique in animal models.

Article continues below and (thank you)
 
The next step is to test the therapy with a different version of the adeno-associated virus; about 200 variations of the virus exist in nature.

"We have another version of the virus that appears in animal studies to be close to a thousandfold more potent at making protein," Flotte said. "That's very encouraging to us. So the next trial, which has already begun, is to use the new version of the virus and take patients through a similar range of doses, in a very similar scheme, and see if we can maintain the safety while pumping up the efficiency of the protein production."

In most people, alpha-1 antitrypsin is made in the liver and protects the lungs by counteracting inflammatory products that destroy lung tissue. But about 100,000 Americans have alpha-1 antitrypsin deficiency, according to the Miami-based Alpha-1 Foundation, a national not-for-profit organization devoted to finding a cure. In addition, medical authorities suspect less than 5 percent of affected individuals are diagnosed, often not until they are in their mid- to late-30s, after extensive lung damage occurs. Shortness of breath, wheezing, chronic cough and recurring chest colds are signs of the disease.

It is important that alpha-1 patients avoid cigarette smoke, said Mark Brantly, M.D., a professor of medicine and molecular genetics and microbiology at UF's College of Medicine who develops clinical research programs aimed at developing therapies for alpha-1 patients. Alpha-1 deficiency can in some patients lead to emphysema and cirrhosis, both progressive diseases that can be fatal.
 
Alpha-1 patients with symptoms of emphysema can be treated through weekly intravenous injections of alpha-1 protein derived from human plasma. The injections must continue throughout a patient's life, according to the American Lung Association. It does not cure, but it does appear to slow the progression of this disease.

Patients in the clinical trial - 10 men and two women who ranged from 42 to 69 - were asked to discontinue their replacement therapy 28 days before receiving the gene therapy.

One volunteer who had not been on protein replacement therapy exhibited low-level expression of alpha-1 antitrypsin, which was detectable 30 days after receiving an injection. However, residual levels of alpha-1 antitrypsin from the replacement therapy in the other patients obscured whether the alpha-1 gene had begun to express protein.

"As the authors conclude, the results set up the more interesting approach of using other AAV serotypes more suited for muscle delivery as an alternative with the same transgene in the next trial," said Richard J. Samulski, a professor of pharmacology and director of the University of North Carolina's Gene Therapy Center. "These studies are important milestones that allow the potential for gene correction of AAT to advance, as well as the (gene therapy) field in general. They also represent the step-by-step process established by the FDA and research community to ensure that safe and good clinical studies are employed in these early days, and I applaud Terry Flotte and his group for being cautious and thorough in their clinical design."

###

The trial is funded by a National Institutes of Health grant, and the Alpha-1 Foundation played a crucial role in helping to build the infrastructure to support the research, Flotte said. UF holds an equity interest in Applied Genetic Technologies Corp., a company formed by UF researchers to develop gene therapies.

Contact: John D. Pastor
University of Florida
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With:News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page